Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early detection of cardiotoxicity in HER2-positive breast cancer patients is possible using circulating microRNAs. These biomarkers, identified soon after anti-HER2 therapy initiation, can predict adverse cardiac events, enabling personalized treatment strategies.
Area Of Science
- Oncology
- Cardiology
- Molecular Biology
Background
- Cardiotoxicity is an increasing concern in HER2-positive breast cancer due to prolonged survival and treatment exposure.
- Early identification of patients at risk for cardiotoxicity is crucial for personalized treatment and follow-up.
- Circulating biomarkers offer a potential avenue for early risk assessment.
Purpose Of The Study
- To investigate the relationship between circulating microRNAs and adverse cardiac events in patients with HER2-positive breast cancer.
- To identify potential microRNA biomarkers for early cardiotoxicity detection during anti-HER2 therapy.
Main Methods
- Plasma samples from the NeoALTTO trial were analyzed at baseline, 2 weeks, and before surgery.
- Circulating microRNAs were profiled in patients who experienced cardiac events (cases) and matched controls.
- MicroRNA expression levels were compared using real-time PCR and the Kruskal-Wallis test.
Main Results
- Eight circulating microRNAs showed differential expression after 2 weeks of anti-HER2 therapy.
- Increased expression of miR-125b-5p, miR-409-3p, miR-15a-5p, miR-423-5p, miR-148a-3p, miR-99a-5p, and miR-320b was observed in cases.
- Decreased expression of miR-642a-5p was noted in cases, with all identified microRNAs linked to cardiomyocyte adrenergic signaling.
Conclusions
- Circulating microRNAs can serve as early biomarkers for cardiotoxicity in breast cancer patients undergoing anti-HER2 therapy.
- Testing microRNA levels early in treatment can identify patients at risk for cardiac events.
- This finding supports the development of personalized cardiotoxicity monitoring and management strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...